January 08, 2014
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Retina specialists examine evolving role of laser therapy in DME treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Laser photocoagulation has long been a mainstay in the treatment of diabetic macular edema associated with diabetic retinopathy, but some retina specialists believe adjunctive use of laser may increase durability of commonly used anti-VEGF agents.
Before anti-VEGFs became the go-to treatment for DME, laser therapy was the norm, according to David M. Brown, MD, FACS.
“The treatment before anti-VEGF was all laser,” Brown said in the cover story of the latest issue of Ocular Surgery News. “However, the gains seen in RISE/RIDE (ranibizumab), VISTA/VIVID (aflibercept) and the DRCR protocols (ranibizumab, aflibercept and bevacizumab) are all superior to anything seen with historical laser trials.”